CNDAC HCl is primarily utilized in the development of anticancer drugs, particularly in the synthesis of nucleoside analogs. These analogs are designed to inhibit DNA replication in cancer cells, thereby halting their proliferation. The compound is a key intermediate in the production of novel chemotherapeutic agents, offering potential in treating various malignancies. Its mechanism involves incorporation into DNA strands, leading to strand breaks and cell death. Research is ongoing to explore its efficacy in combination therapies and its role in overcoming drug resistance in cancer treatment.